SPRB
Spruce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$57.78
+0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 4.9M | 10.1M | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | 4.9M | 10.1M | — |
| Operating Expenses | |||||
| R&D Expense | 28.9M | 19.5M | 46.4M | 49.4M | 35.2M |
| SG&A Expense | 19.0M | 17.0M | 14.6M | 12.7M | 12.1M |
| General & Admin Expense | 19.0M | 17.0M | 14.6M | 12.7M | 12.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 47.8M | 36.5M | 61.1M | 62.1M | 47.3M |
| Cost and Expenses | 47.8M | 36.5M | 61.1M | 62.1M | 47.3M |
| Operating Income (EBIT) | (47.8M) | (36.5M) | (56.2M) | (52.0M) | (47.3M) |
| Non-Operating | |||||
| Interest Income | 522.0K | 1.1M | 3.4M | 4.6M | 1.5M |
| Interest Expense | 1.8M | 90.0K | 307.0K | 483.0K | 420.0K |
| Net Interest Income | (1.3M) | 1.0M | 3.1M | 4.1M | 1.1M |
| Other Non-Op Income/Expense | (3.5M) | (2.5M) | 3.1M | 4.1M | 1.1M |
| Non-Operating Income (excl Interest) | 1.7M | 2.4M | (3.4M) | (4.6M) | (1.5M) |
| EBT (Pre-Tax Income) | (51.4M) | (39.0M) | (53.0M) | (47.9M) | (46.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (51.4M) | (39.0M) | (53.0M) | (47.9M) | (46.2M) |
| Earnings from Cont. Ops | (51.4M) | (39.0M) | (53.0M) | (47.9M) | (46.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.4M) | (39.0M) | (53.0M) | (47.9M) | (46.2M) |
| Per Share | |||||
| Basic EPS | ($40.87) | ($50.83) | ($96.75) | ($93.00) | ($72.00) |
| Diluted EPS | ($40.87) | ($50.83) | ($96.75) | ($93.00) | ($72.00) |
| Revenue Per Share | $0.00 | $0.00 | $9.15 | $20.15 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 2.4M | 766598 | 536444 | 500633 | 611705 |
| Diluted Shares Outstanding | 2.4M | 766598 | 536444 | 500633 | 611705 |
| Profitability Metrics | |||||
| EBITDA | (48.7M) | (38.9M) | (52.7M) | (47.4M) | (45.7M) |
| D&A | 891.0K | 21.0K | 46.0K | 70.0K | 74.0K |
| EBIT | (49.6M) | (38.9M) | (52.7M) | (47.4M) | (45.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026